Trial Profile
A Phase 1 Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and Lapatinib
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jul 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Erlotinib (Primary) ; Lapatinib (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary) ; Trastuzumab (Primary)
- Indications Cancer; HER2 positive breast cancer
- Focus Adverse reactions
- 27 Jun 2020 Status changed from active, no longer recruiting to completed.
- 24 Jan 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.
- 10 May 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.